Shanghai Fosun Pharmaceutical vs Shanghai Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.